z-logo
open-access-imgOpen Access
Immunogenicity and impact on nasopharyngeal carriage of a single dose of PCV10 given to vietnamese children at 18 months of age
Author(s) -
Rachel A. Higgins,
Beth Temple,
Vo Thi Trang Dai,
Thanh Van Phan,
Nguyễn Trọng Toàn,
Leena Spry,
Zheng Quan Toh,
Monica Larissa Nation,
Belinda D. Ortika,
Doan Y. Uyen,
Yin Bun Cheung,
Cattram Nguyen,
Kathryn Bright,
Jason Hinds,
Anne Balloch,
Heidi SmithVaughan,
Tran Ngoc Huu,
Kim Mulholland,
Catherine Satzke,
Paul V. Licciardi
Publication year - 2021
Publication title -
the lancet regional health - western pacific
Language(s) - English
Resource type - Journals
ISSN - 2666-6065
DOI - 10.1016/j.lanwpc.2021.100273
Subject(s) - immunogenicity , context (archaeology) , medicine , serotype , vaccination , carriage , vietnamese , immunology , immune system , biology , pathology , paleontology , linguistics , philosophy
Background This study investigated the immunogenicity and impact on nasopharyngeal carriage of a single dose of PCV10 given to 18-month-old Vietnamese children. This information is important for countries considering catch-up vaccination during PCV introduction and in the context of vaccination during humanitarian crises. Methods Two groups of PCV-naïve children within the Vietnam Pneumococcal Project received PCV10 (n=197) or no PCV (unvaccinated; n=199) at 18 months of age. Blood samples were collected at 18, 19, and 24 months of age, and nasopharyngeal swabs at 18 and 24 months of age. Immunogenicity was assessed by measuring serotype-specific IgG, opsonophagocytosis (OPA) and memory B cells (Bmem). Pneumococci were detected and quantified using real-time PCR and serotyped by microarray. Findings At 19 months of age, IgG and OPA responses were higher in the PCV10 group compared with the unvaccinated group for all PCV10 serotypes and cross-reactive serotypes 6A and 19A. This was sustained out to 24 months of age, at which point PCV10-type carriage was 60% lower in the PCV10 group than the unvaccinated group. Bmem levels increased between 18 and 24 months of age in the vaccinated group. Interpretation We demonstrate strong protective immune responses in vaccinees following a single dose of PCV10 at 18 months of age, and a potential impact on herd protection through a substantial reduction in vaccine-type carriage. A single dose of PCV10 in the second year of life could be considered as part of catch-up campaigns or in humanitarian crises to protect children at high-risk of pneumococcal disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom